Hoth Therapeutics - HOTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 354.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.88
▼ -0.01 (-1.12%)

This chart shows the closing price for HOTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hoth Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOTH

Analyst Price Target is $4.00
▲ +354.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Hoth Therapeutics in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 354.55% upside from the last price of $0.88.

This chart shows the closing price for HOTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Hoth Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00Low
2/5/2024HC WainwrightReiterated RatingBuy$4.00Low
4/10/2023BenchmarkReiterated RatingSpeculative Buy$5.00Low
4/3/2023EF Hutton Acquisition Co. ILower TargetBuy$33.00 ➝ $14.00Low
12/30/2022EF Hutton Acquisition Co. ILower TargetBuy$45.00 ➝ $33.00N/A
5/27/2022BenchmarkLower Target$100.00Low
10/15/2019BenchmarkInitiated CoverageSpeculative Buy$250.00High
(Data available from 7/16/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/17/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
3/18/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Hoth Therapeutics logo
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Read More

Today's Range

Now: $0.88
Low: $0.88
High: $0.92

50 Day Range

MA: $1.04
Low: $0.87
High: $1.22

52 Week Range

Now: $0.88
Low: $0.86
High: $3.37

Volume

16,680 shs

Average Volume

266,354 shs

Market Capitalization

$4.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Hoth Therapeutics?

The following Wall Street analysts have issued reports on Hoth Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for HOTH.

What is the current price target for Hoth Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Hoth Therapeutics in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting HOTH will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for Hoth Therapeutics in the next year.
View the latest price targets for HOTH.

What is the current consensus analyst rating for Hoth Therapeutics?

Hoth Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOTH will outperform the market and that investors should add to their positions of Hoth Therapeutics.
View the latest ratings for HOTH.

What other companies compete with Hoth Therapeutics?

How do I contact Hoth Therapeutics' investor relations team?

Hoth Therapeutics' physical mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company's listed phone number is (646) 756-2997 and its investor relations email address is [email protected]. The official website for Hoth Therapeutics is www.hoththerapeutics.com. Learn More about contacing Hoth Therapeutics investor relations.